Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O15498

UPID:
YKT6_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O15498; B4DR94; Q53F01; Q6FGU9; Q6IB15

BACKGROUND:
The protein Synaptobrevin homolog YKT6, with the unique identifier O15498, is essential for the proper functioning of vesicular transport systems in cells. It serves as a v-SNARE, mediating the docking and fusion of vesicles to their target compartments. YKT6 is involved in key transport pathways, including from the endoplasmic reticulum to the Golgi apparatus and from early/recycling endosomes to the TGN, working within SNARE complexes that include GOSR1, GOSR2, STX5, and BET1L. Its activity as a S-palmitoyl transferase further highlights its role in cellular lipid metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Synaptobrevin homolog YKT6 holds promise for unveiling novel therapeutic avenues. Given its central role in vesicle transport and membrane dynamics, targeting YKT6 could offer new strategies for treating conditions linked to these critical cellular processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.